NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) · CHIMERIC PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9UM73. Start with cancer, then reuse UniProt Q9UM73 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt Q9UM73 as the stable protein anchor across project notes and exports.
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include CERITINIB, CRIZOTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyALK tyrosine kinase receptor
Review this target as NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor), mapped to UniProt Q9UM73. ChEMBL maps the protein component as ALK tyrosine kinase receptor. Sequence length is 1620 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) as ChEMBL target CHEMBL2111387, mapped to UniProt Q9UM73. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) is the right protein anchor across sources, using UniProt Q9UM73 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) |
| Target Type | CHIMERIC PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9UM73 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | ALK tyrosine kinase receptor |
| UniProt Accession | Q9UM73 |
| Component Type | Protein |
| Sequence Length | 1620 aa |
ALK tyrosine kinase receptor
Review this target as NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor), mapped to UniProt Q9UM73. ChEMBL maps the protein component as ALK tyrosine kinase receptor. Sequence length is 1620 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include CERITINIB, CRIZOTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL601719 | 8.7 | IC50 | 2.0 | Approved |
| CHEMBL4762256 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL3545360 | 8.17 | IC50 | 6.8 | Preclinical |
| CHEMBL4762861 | 8.15 | IC50 | 7.0 | Preclinical |
| CHEMBL4798141 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL3651854 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL2403108 | 7.58 | IC50 | 26.0 | Approved |
| CHEMBL2158531 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL4791252 | 7.48 | IC50 | 33.0 | Preclinical |
| CHEMBL2158527 | 7.4 | IC50 | 40.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 26 | 57 | 6.7 |
| protein format | 11 | 1 | 7.5 |
| assay format | 3 | 2 | 8.4 |
| protein complex format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 4 | 5.1 |
| cell-based format | 1 | 3 | 4.9 |